Defects in Energy Metabolism Are Associated with Functional Exhaustion of Bone Marrow Mesenchymal Stem Cells in Cirrhosis
Overview
Authors
Affiliations
Objectives: Cellular and functional exhaustion of bone marrow mesenchymal stem cells (BM-MSC) is significantly associated with the loss of HSCs and hepatic osteodystrophy in cirrhosis. The molecular mechanisms underlying the dysfunction of BM-MSCs are not well understood. We investigated the underlying mechanisms of cellular and functional exhaustion of BM-MSCs in cirrhosis.
Methods: The MSCs were isolated retrospectively from bone marrow of decompensated alcoholic cirrhosis patients {(Trial registration: ClinicalTrials.gov NCT01902511) (n=10; MELD=16.2±2.3; CTP=8.7±2.3)} and age and gender-matched healthy controls (n=8). Global gene expression profile of healthy bone marrow MSCs (hBM-MSCs) and cirrhosis patients BM-MSCs (cBM-MSCs) were done by mRNA sequencing. XFe24-bioanalyzer analyzed the bioenergetic potential of cells. Level of different cytokines and growth factors in BM-plasma and MSCs secretome were analyzed by Luminex-based bead array.
Results: Analysis of differentially expressed genes showed significant (P<0.01) up-regulation of genes associated with ubiquitination and catabolism of proteins; TNF signaling, insulin resistance, and down-regulation of genes associated with DNA repair, protein processing, cell cycle, and mitochondrial respiration in cBM-MSCs in comparison to hBM-MSCs. Compared to hBM-MSCs, cBM-MSCs showed a significant defect in glycolysis due to insulin resistance and poor glucose uptake (P=0.002). This led to compromised self-renewal capacity and cellular loss of MSCs in cirrhosis. cBM-MSCs also showed a significant impairment in Oxidative phosphorylation (OXPHOS) due to mitochondrial dysfunction leading to defects in the osteogenic differentiation with early aging and senescence.
Conclusion: Compromised energy metabolism due to inflammatory and metabolic stress-induced insulin resistance underlies the cellular and functional exhaustion of BM-MSCs in cirrhosis.
Nautiyal N, Maheshwari D, Kumar D, Rao E, Tripathi D, Kumar S Front Immunol. 2024; 15:1439510.
PMID: 39188716 PMC: 11345600. DOI: 10.3389/fimmu.2024.1439510.
Morsczeck C, De Pellegrin M, Reck A, Reichert T Biomedicines. 2023; 11(10).
PMID: 37893160 PMC: 10604663. DOI: 10.3390/biomedicines11102787.
Chen Z, Jiang Y, Wu S, Dang M Medicine (Baltimore). 2023; 102(23):e33963.
PMID: 37335681 PMC: 10256394. DOI: 10.1097/MD.0000000000033963.